Tag:
Eli Lilly
Latest Headlines
Latest Headlines
UPDATED: New cloud hovers over class of 'good cholesterol' drugs
Fresh doubts have cropped up for raising "good cholesterol" to combat heart attack risk, after a new study showed that patients genetically programmed to have higher levels of HDL cholesterol didn't appear to be more protected from heart disease than those with low levels.
Cancer drug developers angling for center stage at ASCO
Later this week the cancer drug research crowd will examine a tsunami of abstracts filed ahead of the ASCO meeting in early June in the hopes of finding a few gems.
Big Pharma's high-risk pursuit of CNS gold faces major market doubts
Here's an interesting number for anyone interested in the risks and rewards of drug development: Two of every three analysts and fund managers recently queried by the ISI Group say they expect that new Alzheimer's drugs in late-stage testing at Eli Lilly and Pfizer/J&J will fail.
Incyte rides wave after Pfizer's FDA panel nod
Incyte's shares jumped this week after agency advisers backed approval of Pfizer's potential blockbuster JAK inhibitor for rheumatoid arthritis.
A strike against sales-rep OT as Lilly, Abbott win appeal
A U.S. appeals court has denied overtime for Eli Lilly and Abbott Laboratories sales reps.
Indian panel accuses Big Pharma of colluding with regulators
An Indian government report has hit the domestic pharma business like a whirlwind--and sucked Big Pharma into the fury.
Amgen, VC groups pump $16.5M into Sutro Biopharma
Skyline Ventures led the second $16.5 million closing of the San Francisco-based startup's Series C round, which included backing from Amgen Ventures, Lilly Ventures, Alta Partners and SV Life Sciences.
Lilly Ventures-backed startup grabs $4.6M round
A secretive startup at Lilly Ventures in Indianapolis has grabbed $4.6 million of a documented $15 million round of equity financing, MedCity News reported, citing SEC documents.
Roche gives up on anticipated 'good cholesterol' drug
Roche's once-promising "good cholesterol" drug candidate is now history.
Roche abandons potential blockbuster cholesterol drug
The Swiss drug giant's failure brings negative attention to similar drugs in development at Merck and Eli Lilly that raise "good" cholesterol to combat cardiovascular disease.
